Abstract:AIM: To investigate the effect of dihydroartemisinin (DHA) on the proliferation of murine T lymphocytes stimulated by Con A in vitro and its related immunosuppressive mechanism. METHODS: Murine T lymphocytes were stimulated by Con A and treated with different concentrations of DHA. Cell proliferation was measured by carboxyl fluoresce in diacetate succinmidyl ester (CFDA-SE) staining. The expression of CD69, CD25 and CD71,which was the marker of early, middle, later activation of CD3~+ T lymphocytes, was measured by flow cytometry (FCM) combined with two-color immunofluorescent staining of cell surface antigen. Fluorescence calcium indicator fluo-4/AM was used to measure the change of the intracellular calcium concentration ([Ca~(2+)]_i) of murine T lymphocytes. The distribution of the cell cycle was analyzed by PI staining. The expression of CD69, the early activation antigen on CD4~+CD25~(high) Treg was also measured by FCM combined with three-color immunofluorescent staining. RESULTS: The result of CFDA-SE staining showed that DHA efficiently inhibited the Con A-induced proliferation of T-lymphocytes in a time-and dose-dependent manners. DHA showed modestly increased proportions of CD69 and CD25 on Con A-stimulated CD3~+T cells, but inhibited the expression of CD25 in a dose dependent manner. DHA with Con A, but not DHA alone, caused an increase in intracellular calcium concentration of T cells. The results of FCM analysis with PI staining showed that DHA imposed a total cell cycle arrest in G_0/G_1 and prevented cells entering S phase and G_2/M phase. Furthermore, DHA reduced the expression of CD69 on CD4~+CD25~(high) Treg. CONCLUSION: DHA, which exhibits immunosuppressive effect on the proliferation of murine T-lymphocytes, is promising to be developed as an immunosuppressive reagent.

[Dihydroartemisinin Inhibits the Expression of Vascular Endothelial Growth Factor in K562 Cells].

Dihydroartemisinin Downregulates Vascular Endothelial Growth Factor Expression and Induces Apoptosis in Chronic Myeloid Leukemia K562 Cells

Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9

Dihydroartemisinin Inhibits Endothelial Cell Tube Formation by Suppression of the STAT3 Signaling Pathway

Dihydroartemisinin Induces Apoptosis of Cervical Cancer Cells Via Upregulation of RKIP and Downregulation of Bcl-2.

Induction of Apoptosis and Inhibition of Cell Migration and Tube-Like Formation by Dihydroartemisinin in Murine Lymphatic Endothelial Cells

Dihydroartemisinin Exhibits Antitumor Activity Toward Hepatocellular Carcinoma in Vitro and in Vivo.

Dihydroartemisinin Inhibits Endothelial Cell Migration Via the TGF-β1/ALK5/SMAD2 Signaling Pathway.

Inhibition of Urokinase-Type Plasminogen Activator Expression by Dihydroartemisinin in Breast Cancer Cells.

Immunosuppressive effect of dihydroartemisinin on murine T lymphocytes

Antimalarial Dihydroartemisinin Also Inhibits Angiogenesis.

Dihydroartemisinin Induces Apoptosis in Human Leukemia Cells Hl60 Via Downregulation of Transferrin Receptor Expression

Dihydroartemisinin Inhibits Proliferation and Induces Apoptosis of U87 Cells by Increasing the Expression of Caspase-3

Effects of Dihydroartemisinin(DHA) regulation of squamous cell carcinoma A431 cells and Hacat cells proliferation and apoptosis

Dihydroartemisinin Induces Autophagy and Inhibits the Growth of Iron-Loaded Human Myeloid Leukemia K562 Cells Via ROS Toxicity.

Dihydroartemisinin Inhibits Angiogenesis In Pancreatic Cancer By Targeting The Nf-Kappa B Pathway

Dihydroartemisinin Down-Regulates the Expression of Transferrin Receptor in Myeloid Leukemia Cells

Inhibitory Effect of Dihydroartemisinin on the Proliferation and Migration of Melanoma Cells and Experimental Lung Metastasis From Melanoma in Mice

Inhibiting Effect of Dihydroartemisinin on Proliferation of Rat Mesangial Cells in Culture

Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K